Gilead, AbbVie still have plenty of hep C patients to treat; Docs, pharmacists mix up Brintellix and Brilinta;

> Next-gen hep C drugmakers Gilead ($GILD) and AbbVie ($ABBV) still have a huge treatable population, with more than 2 million untreated patients remaining in the U.S. Report

> With three products nearing biosimilar competition, Amgen ($AMGN) will be the first to defend its products in the U.S. More

> Shire ($SHPG) has picked up Foresight Biotherapeutics Inc. for $300 million in cash, gaining access to a late-stage experimental pink eye drug. Report

> China is expanding medical insurance to cover all critical illnesses for all urban and rural residents by the end of the year. More

And Finally... Lundbeck and Takeda's antidepressant Brintellix and AstraZeneca's ($AZN) anti-clotting agent Brilinta have been confused at least 50 times by doctors and pharmacists, the FDA says. More

Suggested Articles

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.